LuciBriga (Brigatinib) 180 mg

Indicated for the treatment of adult patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC):

• First-line treatment: For newly diagnosed patients.
• Second-line treatment: For patients whose disease has progressed on or who are intolerant to Crizotinib.

Dosage Form: 180 mg Tablet.

⚠️ CRITICAL DOSING STEP-UP:

Do not start directly with 180 mg.

1. Lead-in Period (Days 1-7): Start with 90 mg once daily to reduce the risk of pulmonary side effects.
2. Maintenance (Day 8+): If tolerated, increase to the standard dose of 180 mg once daily.

💊 Administration: Take once daily with or without food. Swallow the tablet whole.

• Hypersensitivity to Brigatinib.
• Pregnancy and breastfeeding (embryo-fetal toxicity).
• Severe hepatic impairment (caution required).

Regular monitoring is required for:

• Respiratory Symptoms: Cough or dyspnea (signs of pneumonitis/ILD), typically early in treatment.
• Hypertension: High blood pressure.
• Bradycardia: Slow heart rate.
• Hyperglycemia: Elevated blood sugar levels.